Results 221 to 230 of about 1,171,277 (292)

Thromboelastography-Guided Laparoscopic Splenectomy in a Patient With Immune Thrombocytopenia and Recent Drug-Eluting Stent Placement: A Case Report. [PDF]

Case Rep Anesthesiol
Gaona J, Patel J.
europepmc   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag. [PDF]

TH Open
Hill QA, Zaja F, Sánchez de Mora MDCF, Cervinek L, Janssens A, Hosnijeh FS, Le Treust L, Glen F, Putnik M, Rich C, Miesbach W.   +10 more
europepmc   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

European Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Sustained response after rilzabrutinib discontinuation in multirefractory immune thrombocytopenia. [PDF]

Blood Vessel Thromb Hemost
González-López TJ, Orza F, Cuesta-García A, Pérez-Gómez N, Fedele JL, Provan D, Kuter DJ.   +6 more
europepmc   +1 more source

Treatment Patterns, Outcomes and Survival Trends in T‐Cell Prolymphocytic Leukemia: A Nationwide Population‐Based Study in the Netherlands

European Journal of Haematology, EarlyView.
ABSTRACT Background T‐cell prolymphocytic leukemia (T‐PLL) is a rare, aggressive mature T‐cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population‐level outcomes remain poorly defined.
Mirian Brink, Arie C. van der Spek, Jeanette K. Doorduijn, Koen de Heer, Sabina Kersting, Lidwine W. Tick, Doreen G. te Raa, Hanneke M. van der Straaten, Gerrit Jan Veldhuis, Laurens Laterveer, Rogier Mous, Mark‐David Levin, Kees Meijer, Andre Mulder, M. Nijland, Gerwin Huls, Arnon P. Kater, Mar Bellido   +17 more
wiley   +1 more source

Severe Postoperative Epistaxis Revealing Immune Thrombocytopenia: A Case Report. [PDF]

J Rhinol
Oh H, Mun SJ.
europepmc   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Cost-effectiveness analysis of eltrombopag, hetrombopag and romiplostim for second-line treatment of primary immune thrombocytopenia in China. [PDF]

Front Med (Lausanne)
Chen X, Liu Y, Zhang J, Xu R, Guo C.
europepmc   +1 more source

Recombinant ADAMTS13 Ameliorates Liver Injury and Improves Hepatic Microcirculation in a Murine Acute‐on‐Chronic Liver Failure Model

Hepatology Research, EarlyView.
ABSTRACT Aim The therapeutic significance of recombinant a disintegrin‐like and metalloprotease with thrombospondin type 1 motif 13 (rADAMTS13) in acute‐on‐chronic liver failure (ACLF) remains unclear. We aimed to investigate the therapeutic effects of rADAMTS13 in a murine model of ACLF‐like liver injury.
Jun‐ichi Hanatani, Norihisa Nishimura, Kosuke Kaji, Masayoshi Takami, Hiroyuki Masuda, Hiroaki Takaya, Koh Kitagawa, Shinya Sato, Tadashi Namisaki, Hitoshi Yoshiji   +9 more
wiley   +1 more source